Cargando…

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study

BACKGROUND: Egypt has one of the highest (16-8%) prevalence rates of HCV infection in the world. Approximately 90% of Egyptian HCV isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. Studies comparing the efficacy and safety of PEGIFN...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Raziky, Maissa, Fathalah, Waleed Fouad, El-akel, Wafaa Ahmed, Salama, Ahmed, Esmat, Gamal, Mabrouk, Mahassen, Salama, Rabab Mamoun, Khatab, Hany Mahmoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732660/ https://www.ncbi.nlm.nih.gov/pubmed/23922556 http://dx.doi.org/10.5812/hepatmon.10069

Ejemplares similares

Non-Invasive Prediction of Hepatic Fibrosis in Patients With Chronic HCV Based on the Routine Pre-Treatment Workup
por: Khairy, Marwa, et al.
Publicado: (2012)

The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis
por: Khairy, Marwa, et al.
Publicado: (2013)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Efficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects
por: Khedmat, Hossein, et al.
Publicado: (2010)

Interferon-alpha-2a/peginterferon: Various toxicities: 6 case reports
Publicado: (2022)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
por: Druyts, Eric, et al.
Publicado: (2012)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment
por: Nakamura, Masato, et al.
Publicado: (2013)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function
por: Cortés-Telles, Arturo
Publicado: (2016)

The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2010)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
por: Yan, Zehui, et al.
Publicado: (2012)

Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment
por: Gozdas, Hasan Tahsin, et al.
Publicado: (2015)

Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C
por: Wang, Liang-Jen, et al.
Publicado: (2016)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4
por: Shaker, Olfat, et al.
Publicado: (2013)

Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis
por: Ying, Sang-Yu, et al.
Publicado: (2021)

Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV
por: Odolini, Silvia, et al.
Publicado: (2014)

Sexual Dysfunction in Males with Hepatitis C Virus: Relevance to Histopathologic Changes and Peginterferon Treatment
por: El-Atrebi, Kamal A., et al.
Publicado: (2011)

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
por: El-Lababidi, Rania M., et al.
Publicado: (2020)

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007)

Concurrent acute interstitial pneumonia and pulmonary embolism during treatment with peginterferon alpha-2a and ribavirin in a patient with hepatitis C
por: Çoban, Hikmet, et al.
Publicado: (2014)

Peginterferon based therapy for chronic hepatitis C in the elderly patients
por: Bold, Adriana, et al.
Publicado: (2013)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Which is the IDEAL Peginterferon for Hepatitis C: A Meta-Analysis of both Pegylated Interferons in the Treatment of HCV-Infected Patients
por: Tacke, Frank
Publicado: (2010)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

Association of HCV with diabetes mellitus: an Egyptian case-control study
por: Elhawary, Eman I, et al.
Publicado: (2011)

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
por: Li, Wen-cong, et al.
Publicado: (2011)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
por: Barros, Fabio MR, et al.
Publicado: (2013)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Derivation of “Egyptian varices prediction (EVP) index”: A novel noninvasive index for diagnosing esophageal varices in HCV Patients
por: Abd-Elsalam, Shimaa M., et al.
Publicado: (2021)

Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report
por: EL-Atrebi, Kamal, et al.
Publicado: (2009)

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3
por: Powis, J, et al.
Publicado: (2008)

Hepatitis C-Related Cirrhosis with Sustained Prevention of Hepatocellular Carcinoma Recurrence by Long-Term Administration of Super-Low-Dose Peginterferon-Alpha 2b
por: Mamori, Satoshi, et al.
Publicado: (2011)

Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9eicv7r7cqvf7nb85d6i13uofb